The EPS miss relative to consensus may weigh on near-term sentiment, but the strong revenue growth, first operating profit, and positive regulatory catalyst (TransCon CNP EU decision) provide a mixed picture. Watch for the final EC decision on TransCon CNP in Q4 2026 and topline pivotal data in Q3 2027.
Drugs in focus
ASND drug pipeline →lonapegsomatropin
● Neutral Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already approved and marketed (FDA approval August 2021)
- Next catalyst
- None dated
What to watchSkytrofa is a steady commercial contributor but not the primary value driver for ASND anymore, YORVIPATH's rapid growth and the YUVIWEL launch are the main catalysts. Watch for any FDA filing for adult GHD indication (completed Phase 3 data in hand) and quarterly Skytrofa sales trajectory. The stock's next major binary catalyst is the EU MAA decision for YUVIWEL expected in Q4 2026.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 12 $267.07entry
- T+1 · 4d ago +3.12%α +3.48% · $275.39
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ascendis Pharma reported Q3 2026 product revenue of €366M (+89% YoY), driven by YORVIPATH (€291M, +103% YoY). GAAP EPS was €1.08 per diluted share, below the consensus estimate of $1.12 per ADS. The company achieved its first operating profit (€125M, 34% margin) and raised full-year operating cash flow guidance to at least €600M.
Key Financial Metrics
Key Facts
- Q3 2026 product revenue €366M, +89% YoY
- YORVIPATH revenue €291M, +103% YoY
- GAAP diluted EPS €1.08 vs consensus $1.12 (miss)
- Non-IFRS diluted EPS €1.71
- Operating profit €125M (34% margin), first profitable quarter
- Cash flow from operations €189M in Q3; full-year guidance at least €600M
- Cash and equivalents €964M as of Sep 30, 2026
- Year-to-date share repurchases 1,998,999 shares for $459M
- Positive CHMP opinion for TransCon CNP in EU; final EC decision expected Q4 2026
Financial Impact
Q3 product revenue €366M (+89% YoY); GAAP EPS €1.08 vs consensus $1.12
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| YORVIPATH | $290.6M | +103.1% |
| SKYTROFA | $59.4M | +17.2% |
| YUVIWEL | $15.6M | Not reported |
Risk Factors
- EPS missed consensus despite strong revenue growth
- Revenue and EPS reported in EUR, consensus in USD; currency mismatch may affect comparability
- Selling, general & administrative expenses rising faster than revenue (+30% vs +89%)
- Dependence on YORVIPATH for majority of revenue (79% of product revenue)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3401477 |
Track record
41 reports on ASND
14 of 19 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 25 of 27 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $271.73 −1.33% settles Feb 11
- Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 12, 20264d ago Press Release Neutral 5/10 Viewing Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
- Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
- Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers